ECSP22049014A - Variantes de progranulina - Google Patents
Variantes de progranulinaInfo
- Publication number
- ECSP22049014A ECSP22049014A ECSENADI202249014A ECDI202249014A ECSP22049014A EC SP22049014 A ECSP22049014 A EC SP22049014A EC SENADI202249014 A ECSENADI202249014 A EC SENADI202249014A EC DI202249014 A ECDI202249014 A EC DI202249014A EC SP22049014 A ECSP22049014 A EC SP22049014A
- Authority
- EC
- Ecuador
- Prior art keywords
- progranulin
- variants
- proteins
- ftd
- polypeptide
- Prior art date
Links
- 102000019204 Progranulins Human genes 0.000 title abstract 4
- 108010012809 Progranulins Proteins 0.000 title abstract 4
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan en la presente variantes de progranulina y prote?nas de fusi?n que comprenden una variante de progranulina y un polip?ptido Fc. Tambi?n se proporcionan en la presente m?todos para el uso de dichas prote?nas para el tratamiento de trastornos asociados con la progranulina (por ejemplo, una enfermedad neurodegenerativa, tal como demencia frontotemporal (FTD)).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953099P | 2019-12-23 | 2019-12-23 | |
| US202063091819P | 2020-10-14 | 2020-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22049014A true ECSP22049014A (es) | 2022-07-29 |
Family
ID=74184961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202249014A ECSP22049014A (es) | 2019-12-23 | 2022-06-21 | Variantes de progranulina |
Country Status (4)
| Country | Link |
|---|---|
| CL (1) | CL2022001712A1 (es) |
| EC (1) | ECSP22049014A (es) |
| TW (1) | TW202138384A (es) |
| WO (1) | WO2021133907A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| WO2025051953A1 (en) * | 2023-09-07 | 2025-03-13 | Novo Nordisk A/S | Sortilin-1 binders, constructs and uses thereof |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210284701A1 (en) * | 2016-07-14 | 2021-09-16 | Emory University | Granulin Compositions and Uses Related Thereto |
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| WO2018152285A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
-
2020
- 2020-12-23 WO PCT/US2020/066831 patent/WO2021133907A1/en not_active Ceased
- 2020-12-23 TW TW109145722A patent/TW202138384A/zh unknown
-
2022
- 2022-06-20 CL CL2022001712A patent/CL2022001712A1/es unknown
- 2022-06-21 EC ECSENADI202249014A patent/ECSP22049014A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202138384A (zh) | 2021-10-16 |
| WO2021133907A1 (en) | 2021-07-01 |
| CL2022001712A1 (es) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003255A1 (es) | Proteínas de fusión que comprenden progranulina | |
| CO2022008648A2 (es) | Variantes de progranulina | |
| CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
| ECSP22049014A (es) | Variantes de progranulina | |
| CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
| SA520411662B1 (ar) | بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم | |
| MX2020006635A (es) | Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma. | |
| CO2018012096A2 (es) | Proteínas de fusión gdf15 y usos de estas | |
| UY40283A (es) | Método para alterar una propiedad de una planta | |
| CR20190480A (es) | Uso de antagonistas de klk5 para el tratamiento de una enfermedad | |
| CY1122644T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| BR112021014944A2 (pt) | Toxinas apxia, apxiia e apxiiia inativas | |
| PH12020500054A1 (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| JOP20220068A1 (ar) | بروتينات اندماج nkg2d واستخداماتها | |
| ZA202005875B (en) | Lfa3 variants and compositions and uses thereof | |
| AR115565A1 (es) | Proteínas de fusión que comprenden progranulina | |
| EA202190062A1 (ru) | Слитые белки, содержащие програнулин | |
| AR120892A1 (es) | Variantes de progranulina | |
| AR119984A1 (es) | Proteínas de fusión nkg2d y sus usos | |
| AR114938A1 (es) | Variantes de expresión de cdkl5 y proteínas de fusión cdkl5 | |
| UA115420U (xx) | Спосіб відновлення деталей |